Plasminogen activator inhibitor-1 overexpression in nonproliferative diabetic retinopathy

Experimental Eye Research

Volumn 63, Issue 3, 1996, Pages 233-244

  Grant, Maria B ^a,b   Ellis, E Ann ^a   Caballero, Sergio ^a   Mames, Robert N ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

diabetic retinopathy; immunocytochemistry; insulin like growth factor I; plasminogen activator inhibitor; retinal endothelial cells

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR; SOMATOMEDIN C;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; VASCULAR ENDOTHELIUM;

EID: 0030248421     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1006/exer.1996.0112     Document Type: Article

References (44)

1. Alessi, M. C., Juhan-Vague, I., Kooistra, T., Decleck, J. R. and Collen, D. (1988). Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb. Haemost. 60, 491-4.
2. Ashton, N. (1963). Studies in the retinal capillaries in relation to diabetic and other retinopathies. Br. J. Ophthalmol. 47, 521-38.
3. Auwerx, J., Bouillon, R., Collen, D. and Geboers, J. (1988). Tissue-type plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 8, 68-72.
4. Ayo, S. H., Radnik, R. A., Glass II, W. F., Garoni, J. A., Rampt, E. R., Appling, D. R. and Kreisberg, J. I. (1991). Increased extracellular matrix synthesis and mRNA in mesangial cells grown in high-glucose medium. Am. J. Physiol. 260, F185-91.
5. Ayo, S. H., Radnik, R. A., Garoni, J., Glass II, W. F. and Kreisberg, J. I. (1990). High glucose causes an increase in the extracellular matrix proteins in cultured mesangial cells. Am. J. Pathol. 136, 1339-48.
6. Boeri, D., Almus, F. E., Maiello, M., Cagliero, R., Rao, L. V. and Lorenzi, M. (1989). Modification of tissue-factor mRNA and protein response to thrombin and interleukin 1 by high glucose in cultured human endothelial cells. Diabetes 38, 212-8.
7. Brignole, F., Baudouin, C., Roul, C., Gastaud, P. and Bayle, J. (1994). Tissue-type plasminogen activator (TPA) and plasminogen activator inhibitor (PAI) in serum, vitreous and subretinal fluid from patients with proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 35, 2041.
8. Cagliero, E., Grant, M. B. and Lorenzi, M. (1991). Measurement of gene expression in human retinal microvessels by solution hybridization. Invest. Ophthalmol. Vis. Sci. 32, 1439-45.
9. Canfield, A, E., Schor, A. M., Loskutoff, D. J., Schor, S. L. and Grant, M. E. (1989). Plasminogen activator inhibitor-type 1 is a major biosynthetic product of retinal micro vascular endothelial cells and pericytes in culture. Biochem. J. 259, 529-35.
10. Cajot, J. F., Bamat, J., Bergonzelli, G. E., Kruithof, E. K. O., Medcalf, R. L., Testuz, J. and Sordat, B. (1990). Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc. Natl Acad. Sci., U.S.A. 87, 6939-43.
11. Cogan, D. G., Toussaint, D. and Kuwabara, T. (1961). Retinal vascular patterns. IV. Diabetic retinopathy. Arch. Ophthalmol. 66, 366-78.
12. Colucci, M., Paramo, J. A. and Collen, D. (1985). Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J. Clin. Invest. 75, 818-24.
13. Edwards III, C. K., Ghiasuddin, S. M., Schepper, J. M., Yunger, L. M. and Kelley, K. W. (1988). A newly defined property of somatotropin : priming of macrophages for production of superoxide anion. Science 239, 769-71.
14. Engerman, R. L. and Kern, T. S. (1993). Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs. Diabetes 42, 820-5.
15. Frank, R. N. (1994). Etiologic mechanisms in diabetic retinopathy. In Retina (Ed. Ryan, S. J.). Pp. 1243-76. C. V. Mosby: St Louis, U.S.A.
16. Fu, Y. K., Arkins, S., Wang, B. S. and Kelley, K. W. (1991). A novel role of growth hormone and insulin-like growth factor-I. Priming neutrophils for superoxide anion secretion. J. Immunol. 146, 1602-8.
17. Garner, A. (1993). Histopathology of diabetic retinopathy in man. Eye 7, 250-3.
18. Gram, J. and Jespersen, J. (1991). Induction and possible role of fibrinolysis in diabetes mellitus. Semin. Thromb. Hemost. 17, 412-6.
19. Grant, M. B., Wargovich, T. J., Ellis, E. A., Caballero, S., Mansour, M. and Pepine, C. J. (1994). Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cells: a potential treatment for restenosis. Circulation 89, 1511-7.
20. Grant, M. B., Ellis, E. A. and Caballero, S. (1994). Role of insulin-like growth factor-I in proliferative diabetic retinopathy : a modulator of free radical-derived oxidant generation. In Recent Advances in Endothelial Cell Dysfunction in Diabetes (Eds. King, G. L. and Shigeta, Y.). Pp. 265-280. Churchill Livingstone: Osaka.
21. Grant, M. B., Mames, R. N., Fitzgerald, C., Ellis, E. A., Aboufriekha, M. and Guy, J. (1993). Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina : comparative studies with basic fibroblast growth factor. Diabetologia 36, 282-91.
22. Grant, M. B. and Guy, J. (1991). Plasminogen activator production by human retinal endothelial cells of non-diabetic and diabetic origin. Invest. Ophthalmol. Vis. Sci. 32, 53-64.
23. Grant, M. B., Russell, B., Fitzgerald, C. and Merimee, T. J. (1986). Studies in control and diabetic subjects with neovascularization. Diabetes 35, 416-20.
24. Hamsten, A., Wiman, B., de Faire, V. and Blomback, M. (1985). Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N. Engl. J. Med. 313, 1557-63.
25. Kruithof, E. K., Tran-Thang, C., Gudinchet, A., Hauert, J., Nicoloso, G., Genton, C., Welti, H. and Bachmann, F. (1987). Fibrinolysis in pregnancy. A study of plasminogen activator inhibitors. Blood 69, 460-6.
26. Loskutoff, D. J. (1991). Regulation of PAI-1 gene expression. Fibrinolysis 5, 197-206.
27. Lufkin, E. G., Pass, D. N., O'Fallon, W. M. and Bowie, E. J. (1979). Increased von Willebrand factor in diabetes mellitus. Metabolism 28, 63-6.
28. Lutty, G. A., Ikeda, K., Chandler, C. and McLeod, D. S. (1991). Immunolocalization of tissue plasminogen activator in the diabetic and nondiabetic retina and choroid. Invest. Ophthalmol. Vis. Sci. 32, 237-45.
29. Maiello, M., Boeri, D., Podesta, F., Cagliero, E., Vichi, M., Odetti, P., Adezati, L. and Lorenzi, M. (1992). Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose. Diabetes 41, 1009-15.
30. Merimee, T. J., Zapf, J. and Froesch, E. R. (1983). Insulin-like growth factors: studies in diabetics with and without retinopathy. N. Engl. J. Med. 309, 527-30.
31. Meyer-Schwickerath, R., Pfeiffer, A., Blum, W. F., Freyberger, H., Klein, M., Losche, C., Rollmann, R. and Schatz, H. (1993). Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. J. Clin. Invest. 92, 2620-5.
32. Michaelson, I. C. (1948). The mode of development of retinal vessels. Trans. Ophthalmol. Soc. U.K. 68, 137-80.
33. Munjal, I. D., Maclean, N. V., Grant, M. B. and Blake, D. A. (1994). Differences in the synthesis of secreted proteins in human retinal endothelial cells of diabetic and nondiabetic origin. Curr. Eye Res. 13, 303-10.
34. Nachman, R. L., Hajjar, K. A., Silverstein, R. L. and Dinarello, C. A. (1986). Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor. J. Exp. Med. 163, 1595-600.
35. Phan-Thanh, L., Robert, L., Derouette, J. C. and Labat-Robert, J. (1987). Increased biosynthesis and processing of fibronectin in fibroblasts from diabetic mice. Proc. Natl Acad. Sci. U.S.A. 84, 1911-5.
36. Pollanen, J., Stephens, R. W. and Vaheri, A. (1991). Directed plasminogen activation at the surface of normal and malignant cells. Adv. Cancer Res. 57, 273-328.
37. Poulsom, R., Kurkinen, M., Prockop, D. J. and Boot-Handford, R. P. (1988). Increased steady-state levels of laminin B1 mRNA in kidneys of long term streptozotocin-diabetic rats: no effects of aldose reductase inhibitors. J. Biol. Chem. 263, 10072-6.
38. Roy, S., Sala, R., Cagliero, E. and Lorenzi, M. (1990). Overexpression of fibronectin induced by diabetes or high glucose : a phenomenon with a memory. Proc. Natl Acad. Sci. USA 87, 404-8.
39. Saksela, O. and Rifkin, D. B. (1988). Cell-associated plasminogen activation: regulation and physiological functions. Annu. Rev. Cell Biol. 4, 93-126.
40. Schneider, D. J., Nordt, T. K. and Sobel, B. E. (1992). Stimulation by proinsulin of expression of plasminogen activator inhibitor type-1 in endothelial cells. Diabetes 41, 890-5.
41. Sundell, I. B., Nilsson, T. K., Hallmans, G., Hellsten, G. and Dahlen, G. H. (1989). Interrelationships between plasma levels of plasminogen activator inhibitor, lipoprotein (a), and established cardiovascular risk factors in a north Swedish population. Atherosclerosis 80, 9-16.
42. Small, M., Kluft, C., MacCuish, A. C. and Lowe, G. D. (1989). Tissue plasminogen activator inhibition in diabetes mellitus. Diabetes Care 12, 655-8.
43. Tabernero, M. D., Estelles, A., Vicente, V., Alberca, I. and Aznar, J. (1989). Incidence of increased plasminogen activator inhibitor in patients with deep venous thrombosis and/or pulmonary embolism. Thromb. Res. 56, 565-70.
44. Tomooka, S., Border, W. A., Marshall, B. C. and Noble, N. A. (1992). Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int. 42, 1462-9.